News & Updates
Filter by Specialty:
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
05 Mar 2022
Minor changes in glucose levels first week after COVID-19 vaccine
Patients with type 1 diabetes mellitus (T1DM) may experience a temporary change in their blood glucose levels in the first week following COVID-19 vaccination, according to a small English study.
Minor changes in glucose levels first week after COVID-19 vaccine
03 Mar 2022
Health benefits from mobile app plus smart band wane once usage stops
A mobile health intervention combining a smartphone app, a smart band, and counseling offers benefits in terms of weight loss, body composition variables, and time spent in light physical activity compared to counseling alone at 3 months among sedentary adults with overweight or obesity, results of the Evident 3 Study have shown.
Health benefits from mobile app plus smart band wane once usage stops
02 Mar 2022
NOACs better than warfarin in diabetic patients with atrial fibrillation
Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.
NOACs better than warfarin in diabetic patients with atrial fibrillation
01 Mar 2022
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.
